Financings
Hemostemix Closes $360,000 First Tranche of Private Placement
Pre-revenue stem cell therapy developer advancing ACP-01 across ischemic indications while navigating severe liquidity constraints and ongoing dilutive financings.
Executive Summary
- Hemostemix Inc. closed the first tranche of its previously announced $1,000,000 non-brokered private placement.
- The company raised CDN$360,000 by issuing 7,200,000 units at CDN$0.05 per unit.
- Each unit consists of one common share and one-half of a common share purchase warrant.
- Warrants carry a CDN$0.12 exercise price and a 24-month term, with an acceleration clause if the stock trades at or above CDN$0.15 for 10 consecutive days.
- Proceeds are earmarked for sales, marketing, patient acquisition, physician education, ACP-01 manufacturing, Bahamas regulatory filings, and general working capital.
- The offering remains subject to final TSX Venture Exchange acceptance and carries a statutory 4-month + 1-day hold period.
- This follows the June 17, 2026 announcement of the $1M placement and a financial restatement regarding Therapeutic Convertible Debentures (TCDs).
Material Impact
- The $360,000 tranche provides immediate, albeit limited, liquidity to a company with only $171,584 CAD in cash and a $1.37M working capital deficit.
- At a $0.05 price, the placement is highly dilutive, issuing 7.2M new shares/warrants against a ~197.8M share count.
- The funds extend operational runway by approximately 3 to 4 months, assuming the current ~$800,000 CAD quarterly burn rate continues.
- The financing is a direct follow-up to the June 17 announcement, meaning the market was already aware of the capital raise.
- The restatement disclosed on June 17 was primarily non-cash (reclassifying TCDs to FVTPL), so it does not alter the cash position or operational strategy, but it highlights internal control weaknesses.
HEM · Price
Company Overview
- Hemostemix Inc. is a pre-revenue clinical-stage biotechnology company focused on ACP-01 (VesCell™), an autologous angiogenic cell precursor therapy.
- The platform targets ischemic and vascular conditions, including chronic limb-threatening ischemia (CLTI), refractory angina, cardiomyopathy, and vascular dementia.
- The company has leveraged regulatory pathways like Florida's SB 1768 to begin commercializing the therapy outside of traditional FDA approval, alongside pursuing a Phase I basket protocol for FDA clearance.
- Strategic initiatives include acquiring cardiology practices in the Dominican Republic to build a clinic roll-up model and partnering with Indigenous healthcare groups in Canada.
- The company holds a "KNOW YOUR HEALTH" trademark in Japan and has published peer-reviewed data highlighting safety and efficacy in early-stage trials.
More from Hemostemix Inc.
Jun 17, 2026 · 17:23